ZVRAZevra Therapeutics Inc. Common Stock

Zevra Therapeutics (NasdaqGS:ZVRA) reported new long term real world safety and effectiveness data for arimoclomol in adults with Niemann Pick disease type C. The publication marks the first extensive evaluation of arimoclomol outside clinical trials and provides fresh clinical insight for patients and prescribers. Alongside the data, Zevra is pursuing regulatory options in Europe after a negative EMA opinion on arimoclomol and continues to support expanded access programs. Zooming out from...

Zevra Therapeutics (NASDAQ:ZVRA) reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA. Net U.S. revenue for MIPLYFFA totaled $30.2 million during the quarter, increas

Zevra Therapeutics Inc (ZVRA) posts strong Q2 2026 results with $39.7 million in revenue and net income of $8.8 million, while navigating EU regulatory challenges for arimoclomol.

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

On Friday, Zevra announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on its application to market arimoclomol for Niemann-Pick disease type C.

The company plans to seek a re-examination after the European regulator’s advisory committee issued a negative opinion on arimoclomol for Niemann-Pick disease type C. Key Investor TakeawaysZevra Therapeutics (NASDAQ:ZVRA) received a negative CHMP opinion on the European Marketing Authorization Application for arimoclomol.

The European Medicines Agency recommended refusal of the marketing authorization for Zevra’s Meplyffa, a medicine intended for the treatment of Niemann-Pick disease type C.